COMP <GO>
LXEO vs IKT // GROSS PROFIT MARGIN
Lexeo Therapeutics Inc. (NASDAQ) VS. Inhibikase Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: LXEO 2
— IKT 0
■ METRIC PARITY
LAST: $3.14 (+2.61%) • MKT CAP: $251.1M
gross-margins
—
LAST: $1.55 (-7.19%) • MKT CAP: $233.0M
gross-margins
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LXEO VS. IKT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LXEO | IKT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -11.93% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 2/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.1 | 33.6 | +12.48 | LXEO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $251.1M | $233.0M | $18.0M | LXEO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LXEO REV | IKT REV | LXEO GROSS % | IKT GROSS % | LXEO FCF | IKT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$99.0M | -$27.8M |
| FY 2024 | $0 | $0 | — | — | -$81.6M | -$19.1M |
| FY 2023 | $0 | $260.5K | — | — | -$59.5M | -$18.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LXEO // BETA —
IKT // BETA —